267 related articles for article (PubMed ID: 25498507)
21. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
22. Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT.
Zhao XS; Jin S; Zhu HH; Xu LP; Liu DH; Chen H; Liu KY; Huang XJ
Bone Marrow Transplant; 2012 Apr; 47(4):499-507. PubMed ID: 21643023
[TBL] [Abstract][Full Text] [Related]
23. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity.
Zhao XS; Yan CH; Liu DH; Xu LP; Liu YR; Liu KY; Qin YZ; Wang Y; Huang XJ
Ann Hematol; 2013 Aug; 92(8):1111-9. PubMed ID: 23680867
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis.
Válková V; Polák J; Marková M; Vítek A; Hájková H; Sálek C; Procházka B; Cetkovský P; Trněný M
Clin Transplant; 2013; 27(1):E21-9. PubMed ID: 23231003
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
[TBL] [Abstract][Full Text] [Related]
26. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
[TBL] [Abstract][Full Text] [Related]
27. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
[TBL] [Abstract][Full Text] [Related]
28. Post-Transplantation Multicolored Flow Cytometry-Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia.
Klyuchnikov E; Badbaran A; Massoud R; Fritsche-Friedland U; Janson D; Ayuk F; Christopeit M; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 May; 28(5):267.e1-267.e7. PubMed ID: 35066212
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
Díez-Campelo M; Pérez-Simón JA; Pérez J; Alcoceba M; Richtmon J; Vidriales B; San Miguel J
Am J Hematol; 2009 Mar; 84(3):149-52. PubMed ID: 19123459
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
Weisser M; Kern W; Rauhut S; Schoch C; Hiddemann W; Haferlach T; Schnittger S
Leukemia; 2005 Aug; 19(8):1416-23. PubMed ID: 15920493
[TBL] [Abstract][Full Text] [Related]
32. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
33. Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation.
Rautenberg C; Pechtel S; Hildebrandt B; Betz B; Dienst A; Nachtkamp K; Kondakci M; Geyh S; Wieczorek D; Haas R; Germing U; Kobbe G; Schroeder T
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2337-2343. PubMed ID: 29753838
[TBL] [Abstract][Full Text] [Related]
34. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
Chen JS; Hsiao CC; Sheen JM; Cheng CN
Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
[TBL] [Abstract][Full Text] [Related]
35. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Dominietto A
Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
[TBL] [Abstract][Full Text] [Related]
37. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):958-66. PubMed ID: 23542687
[TBL] [Abstract][Full Text] [Related]
38. Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation.
Pan X; Gao M; Sun Y; Zhou Y; Wang K; Wang Y; Xu L; Zhang X; Huang X; Zhao XS
Int J Lab Hematol; 2022 Jun; 44(3):510-517. PubMed ID: 35061336
[TBL] [Abstract][Full Text] [Related]
39. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
[TBL] [Abstract][Full Text] [Related]
40. [Detecting minimal residual disease status in allogeneic hematopoietic stem cell transplantation of patients with high-risk acute leukemia].
Shi XL; Tang XW; Wei XA; Zhao BR; Zhou QL; Ye F; Lu YX; Sun XW; Zhu MQ; Shen WH; Qiu HY; Sun AN; Wu DP
Zhonghua Yi Xue Za Zhi; 2011 Oct; 91(38):2692-6. PubMed ID: 22321979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
